E-ISSN 2231-3206 | ISSN 2320-4672
 

Original Research

Online Publishing Date:
17 / 01 / 2023

 


Randomized and parallel-group study of cost-effectiveness analysis of escitalopram and desvenlafaxine in moderate-to-severe depression

Girish K, Moulya Nagaraj, Pavithra M S, Jyothi R, Lakshmi Pandith.


Abstract
Background: Cost-effectiveness analysis (CEA) measures costs and outcomes in monetary terms, it can be used to compare net benefits of all types of interventions. CEA is most important for chronic conditions such as depression requiring long-term/lifelong medications. Depression is a mood disorder affecting all age groups with a considerable impact on the quality of life. It imposes an economic burden on the individual, family, and society. Among antidepressants, selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors are commonly preferred since they are well-tolerated and efficacious. As there are only few studies done in Indian population to compare the efficacy and tolerability of Escitalopram and Desvenlafaxine, and no CEA have been done to compare the cost-effectiveness of Escitalopram and Desvenlafaxine, the present study was taken up. Therefore, the present study was undertaken.

Aims and Objectives: The aim of the study was to evaluate the cost-effectiveness of Escitalopram and Desvenlafaxine in the treatment of moderate-to-severe depression.

Materials and Methods: A randomized, open-label, standard controlled, parallel-group, and 8-week study of CEA of Escitalopram and Desvenlafaxine was performed in 60 subjects with newly diagnosed moderate-to-severe depression. Clinical improvement was assessed using the montgomery and asberg depression rating scale (MADRS). CEA was analyzed using average cost-effectiveness ratio (ACER) and increment cost-effectiveness ratio (ICER).

Results: Escitalopram and Desvenlafaxine showed a significant reduction in the total MADRS scores. Escitalopram showed a faster onset of action and was more efficacious than Desvenlafaxine in reducing depressive symptoms. ACER shows a lesser cost required for Escitalopram over Desvenlafaxine. Negative ICER and increment net benefit analysis demonstrate that Escitalopram is cost-effective versus Desvenlafaxine. Study drugs were well tolerated, with mild nausea in the Desvenlafaxine group.

Conclusion: Escitalopram was more cost-effective in comparison to Desvenlafaxine in moderate to severe depression.

Key words: Depression; Escitalopram; Desvenlafaxine; Cost Effectiveness Analysis


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Girish K
Articles by Moulya Nagaraj
Articles by Pavithra M S
Articles by Jyothi R
Articles by Lakshmi Pandith
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

K G, Nagaraj M, S PM, R J, Pandith L. Randomized and parallel-group study of cost-effectiveness analysis of escitalopram and desvenlafaxine in moderate-to-severe depression. Natl J Physiol Pharm Pharmacol. 2023; 13(2023, Vol: 13, Issue: 8): 1644-1649. doi:10.5455/njppp.2023.13.12618202209012022


Web Style

K G, Nagaraj M, S PM, R J, Pandith L. Randomized and parallel-group study of cost-effectiveness analysis of escitalopram and desvenlafaxine in moderate-to-severe depression. https://www.njppp.com/?mno=134559 [Access: March 14, 2024]. doi:10.5455/njppp.2023.13.12618202209012022


AMA (American Medical Association) Style

K G, Nagaraj M, S PM, R J, Pandith L. Randomized and parallel-group study of cost-effectiveness analysis of escitalopram and desvenlafaxine in moderate-to-severe depression. Natl J Physiol Pharm Pharmacol. 2023; 13(2023, Vol: 13, Issue: 8): 1644-1649. doi:10.5455/njppp.2023.13.12618202209012022



Vancouver/ICMJE Style

K G, Nagaraj M, S PM, R J, Pandith L. Randomized and parallel-group study of cost-effectiveness analysis of escitalopram and desvenlafaxine in moderate-to-severe depression. Natl J Physiol Pharm Pharmacol. (2023), [cited March 14, 2024]; 13(2023, Vol: 13, Issue: 8): 1644-1649. doi:10.5455/njppp.2023.13.12618202209012022



Harvard Style

K, G., Nagaraj, . M., S, . P. M., R, . J. & Pandith, . L. (2023) Randomized and parallel-group study of cost-effectiveness analysis of escitalopram and desvenlafaxine in moderate-to-severe depression. Natl J Physiol Pharm Pharmacol, 13 (2023, Vol: 13, Issue: 8), 1644-1649. doi:10.5455/njppp.2023.13.12618202209012022



Turabian Style

K, Girish, Moulya Nagaraj, Pavithra M S, Jyothi R, and Lakshmi Pandith. 2023. Randomized and parallel-group study of cost-effectiveness analysis of escitalopram and desvenlafaxine in moderate-to-severe depression. National Journal of Physiology, Pharmacy and Pharmacology, 13 (2023, Vol: 13, Issue: 8), 1644-1649. doi:10.5455/njppp.2023.13.12618202209012022



Chicago Style

K, Girish, Moulya Nagaraj, Pavithra M S, Jyothi R, and Lakshmi Pandith. "Randomized and parallel-group study of cost-effectiveness analysis of escitalopram and desvenlafaxine in moderate-to-severe depression." National Journal of Physiology, Pharmacy and Pharmacology 13 (2023), 1644-1649. doi:10.5455/njppp.2023.13.12618202209012022



MLA (The Modern Language Association) Style

K, Girish, Moulya Nagaraj, Pavithra M S, Jyothi R, and Lakshmi Pandith. "Randomized and parallel-group study of cost-effectiveness analysis of escitalopram and desvenlafaxine in moderate-to-severe depression." National Journal of Physiology, Pharmacy and Pharmacology 13.2023, Vol: 13, Issue: 8 (2023), 1644-1649. Print. doi:10.5455/njppp.2023.13.12618202209012022



APA (American Psychological Association) Style

K, G., Nagaraj, . M., S, . P. M., R, . J. & Pandith, . L. (2023) Randomized and parallel-group study of cost-effectiveness analysis of escitalopram and desvenlafaxine in moderate-to-severe depression. National Journal of Physiology, Pharmacy and Pharmacology, 13 (2023, Vol: 13, Issue: 8), 1644-1649. doi:10.5455/njppp.2023.13.12618202209012022